Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2017

Study Completion Date

December 31, 2017

Conditions
Stage IA Pancreatic AdenocarcinomaStage IB Pancreatic AdenocarcinomaStage IIA Pancreatic AdenocarcinomaStage IIB Pancreatic Adenocarcinoma
Interventions
DRUG

Gemcitabine

Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

DRUG

Metformin

Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

DRUG

placebo

Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Trial Locations (1)

200032

Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai

All Listed Sponsors
lead

Xian-Jun Yu

OTHER

NCT02005419 - Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | Biotech Hunter | Biotech Hunter